GlaxoSmithKline plc (LON:GSK) insider Dominic Redfern bought 10 shares of GlaxoSmithKline stock in a transaction on Wednesday, January 10th. The stock was purchased at an average price of GBX 1,333 ($18.08) per share, for a total transaction of £133.30 ($180.77).

Dominic Redfern also recently made the following trade(s):

  • On Monday, December 11th, Dominic Redfern bought 9 shares of GlaxoSmithKline stock. The stock was purchased at an average price of GBX 1,302 ($17.66) per share, for a total transaction of £117.18 ($158.91).

GlaxoSmithKline plc (LON:GSK) traded down GBX 0.40 ($0.01) during midday trading on Thursday, hitting GBX 1,330.60 ($18.04). 8,954,388 shares of the stock were exchanged, compared to its average volume of 8,500,000. GlaxoSmithKline plc has a one year low of GBX 1,270 ($17.22) and a one year high of GBX 1,724.50 ($23.39). The firm has a market cap of $65,970.00 and a P/E ratio of 2,772.08.

GlaxoSmithKline (LON:GSK) last posted its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%. The company had revenue of GBX 784.30 billion during the quarter.

The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.41%. The ex-dividend date is Thursday, November 9th.

GSK has been the topic of a number of recent research reports. Societe Generale restated a “sell” rating on shares of GlaxoSmithKline in a report on Thursday, November 9th. Berenberg Bank reduced their target price on shares of GlaxoSmithKline from GBX 1,835 ($24.88) to GBX 1,760 ($23.87) and set a “buy” rating on the stock in a report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($19.66) target price on shares of GlaxoSmithKline and gave the company a “sell” rating in a report on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($21.83) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Friday, October 27th. Finally, Barclays restated an “equal weight” rating and issued a GBX 1,450 ($19.66) target price on shares of GlaxoSmithKline in a report on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,555.24 ($21.09).

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/dominic-redfern-buys-10-shares-of-glaxosmithkline-plc-gsk-stock/1803052.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.